{"name":"GenSight Biologics","slug":"gensight-biologics","ticker":"","exchange":"","domain":"gensightbiologics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GS010","genericName":"GS010","slug":"gs010","indication":"Leber hereditary optic neuropathy (LHON) due to ND4 mutation","status":"phase_3"}]}],"pipeline":[{"name":"GS010","genericName":"GS010","slug":"gs010","phase":"phase_3","mechanism":"GS010 is a gene therapy that delivers a functional copy of the ND4 gene to restore mitochondrial function in retinal cells affected by Leber hereditary optic neuropathy.","indications":["Leber hereditary optic neuropathy (LHON) due to ND4 mutation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNNzg2TG1VWW1CdXdkQUFuUzRVd0JGQ0x0OEMyQ2p6OWh1QjRnXy1fUXQzTFJyRkpWdEVaZ0t6R21qelJjVEpjRzdTMnU1S0M4dVphZ1o1aGhiVEx6ams2QjFVQ1ROSkV0RkwtU1c0SjVDZUJoZ1JLczFveEhXekxHOGtadF9IR193bVhMVFhiSThlNk9TaFl2TVYzcVA1ajFMbjFqbDRmTkJnMXVKUmh0YldiZVh6QkVWSnM3QUpCTmhYdEh3c3RMS2NlOWo4NzNQMkhaVmp6Q0Vmdnp6OUNsT2hONWh4ek5ZZDRIdWFXeDJKbm5kbjlNY05lMnhyTzRGRkRaeXlFZFM4MUtVbmg1M1BKWFc?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQTERpc1BHcXpidjBHTHl0ekNfeVpDZ1M3SlJnNzhoN044UWVxd1VqMzR4dmJpVVZ0ekRlUjhabFNmV1FTNkRGTTRBRl9FSERCUXdIaks4aGw5LWVzUmJQNGZzUkJuM3p4Slcxcy1jV2VPZDk4dEFNc295aUNhVHJpZFZhVUV5S2k0bVF5ZmlFUTBpcFgxelNvQjZ3NA?oc=5","date":"2026-02-17","type":"regulatory","source":"Yahoo Finance","summary":"GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments - Yahoo Finance","headline":"GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPZTVoM1JKTVZ6Z2J6VXVIam41N0s2WjJQcER5T0lmZHF2X3U4SGtBVmFXNUpNSktUdGpaa0MzQXhubDAxUzVrbnBzaHN3OFRVbDdPQkVKY3p6U2ZFSGl4T2Y1VHdDZzVwUnJadEJyeXpSRkxEVXVLa0hneDZTaDhBVFFGQnBWcEpWeFNkVWo5dDlaZDcybUUtSjNYRU9NTnVBbXVVa2U5SU1CS2doc2tGMzFSSWw5OHBUMGVlZmxPOHNqZDIyaXJTSV9HamluR19vWnc?oc=5","date":"2026-01-29","type":"pipeline","source":"BioSpace","summary":"GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 - BioSpace","headline":"GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxPQllIMkZFaGIyZWdELThSWU9wZnVBYWdtRVlNcnpJaXdCN3ZlUVZLUmpWLVAyU3Vsa1hyZC1ybE5hcVdsSFlkTGg0UElUQkZibVlRMVlLNkMxWkxJWmhXbGJDZWx1SUxDdUJ3UXR1ZjRrcnd1RGhRTlgzZkU4UnMxUUNxQnVfNmNSRW9JVDVNSVIxMEJrRXRsS2pQTGg3Y2ZMcE9sUGV6bFNxR21OY1NwNHVLUFZwZEdidHF6YjAtcFd5dzU1aHh6YU53SWtJclQtSy1KZnZVZ3lGd2xzS1BDT3Vuaw?oc=5","date":"2025-12-23","type":"regulatory","source":"BioSpace","summary":"GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel - BioSpace","headline":"GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-05","type":"trial","source":"GlobeNewswire","summary":"AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire","headline":"AAV for the Hereditary Retinal Diseases Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5MdjZDb2Mxb1hzQ2t1WmFfdF85QTBvZUNwWEpkOHlFbldIT2xJYlpjYlMyMENJbllfTENqM293bFh3SDc1V2RvWWEtLTZPY3ljbm1r?oc=5","date":"2025-02-12","type":"trial","source":"FirstWord Pharma","summary":"GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ Gene Therapy at the Conclusion of the REFLECT Study - FirstWord Pharma","headline":"GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ Gene Therapy at the Conclusion of the REF","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNUktGeXlVZXduenJpUFdVQ0JrUHJ6Y0pKdGNLZXFPczBPdUhJcmd0LUgwUUhjb1RtMTZUV3VXX1ZTZzlNYmZvMWJabnZPTWVqX2YzV2g5eERvMHRRbG9HQklnc1RQbTVqNDBTVGw2b1pSdnItbm5WZTcwdDJCUkYzbWNYZ3dsNm1k?oc=5","date":"2024-10-26","type":"pipeline","source":"Grand View Research","summary":"South Korea Gene Therapy Market Size & Outlook, 2023-2030 - Grand View Research","headline":"South Korea Gene Therapy Market Size & Outlook, 2023-2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOLXJrQTRkOTAxbjVGWGYxbngzNV92aFllemJIUnZZT2ZDWTNOenNZdFNpZHhXb2MzTGFHTFZtQURpWkp2WDZONXZFbkJPT1dBSFdIRjZqRnViWDhnbi0tOExmaXdRbjF2MXh2a1dIQWlHSjZxTGRpdllOa0d3cUE3ckRhWEEzSW9iRjBoRTFiaXhrOE04NFplczgtcmlvcDVpT2lwbFA1SFVIamtKYnhFZ0FTVXN6SUt3dE93YXBTbFE0Z1l3MkdwRTVWWFhjb1dRb091NUFYUXFvNkFFelZ4NmRfdl80MExsRkpLY2FXWjFFN0Z2eWNkczVpOXM?oc=5","date":"2024-08-13","type":"trial","source":"European Medical Journal","summary":"Idebenone Treatment for Leber Hereditary Optic Neuropathy: Time to Clinically Relevant Recovery in the LEROS Study - European Medical Journal","headline":"Idebenone Treatment for Leber Hereditary Optic Neuropathy: Time to Clinically Relevant Recovery in the LEROS Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNUVpHRjR1V2VoZDRwbXY4TV94NW5Zdmp5SEEyVk9FYkNSQzhObHVKWUFpSDVQWnFFaW41azFYX24tdUR3VGcxRnZja3c2b2MyeWdYeUtUWVFWajBBNTV4YUlxRXlHSTdlaG9VRjd3Y1RnbFZIeFpMbjVsQjFkWU81UExVV2cyOVpOX0dRNzJGUEhOd05uOGVxVnpiMVBRUmJY?oc=5","date":"2023-04-21","type":"regulatory","source":"BioPharma Dive","summary":"French biotech pulls EMA application for eye disease gene therapy - BioPharma Dive","headline":"French biotech pulls EMA application for eye disease gene therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQnJzck5HQnI4SWhDeUxsYkhSdkFSWG9oN3M2YVdvM0tMRlVRbnVNR0I3X1JJY1YxSDNkeXdSVTdITU85aVlHRVMtVDdvOXZtcHM5VzNIMGZuT3ZrRXlXMUhzdUF0Y2V0S3pCSGIxWV81UDhXMHlkQ3E0ZDlPUVBTRnlibVBBZTFuSGpV?oc=5","date":"2023-03-10","type":"pipeline","source":"drugdiscoverytrends.com","summary":"The top 100 cell and gene therapy companies to watch in 2023 - drugdiscoverytrends.com","headline":"The top 100 cell and gene therapy companies to watch in 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOeUZwWTUxdTZBUnFqNFRVWFFfVFBhTElJUWQ0STNKaTJsbkJiTUo5TTlYT3VtX19yVVFLT05FYmZ2MDltVVRMaVhMbjRvZ2xBRmFXM2RtazNWOXd0Z0V0cjNOYkVKU3dEQUZDVldFVERQeThuVUFEVnVnZXJ2TlFEN1lHS1p0bFZDVFZ1NXU3Z1dQSEZyNFE5UGFmNjJpSE14cFBwXzZHVmlhNWlO?oc=5","date":"2022-07-19","type":"pipeline","source":"Fierce Biotech","summary":"Roche tasks Avista with scAAVenging for better eye disease gene therapy vectors - Fierce Biotech","headline":"Roche tasks Avista with scAAVenging for better eye disease gene therapy vectors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQbVU3MTdZOTNPeThzcXItVFh3dzA3Z0E5bmxNU1ZObnBRQXpuWmFJMUgxeVdDRkNKT0NvZ0JmSWJNSmRfbTVQN1dYN3hmdnRwS2xiRDJTaTUzLWUtUU5Gcm9VdkpfeUJ3aGJ2Z0tOdW53enpFOF9LMWRDRkJPMG9uX3c5aHZkMzdTMVRWYVZWajZ4aEQzcTlhaUR4RkpudEVtRmVhQnJ2MmpwNm8tc3lHc1lyRHNzQ2dTM3FVU0JhYjNCZw?oc=5","date":"2020-10-14","type":"pipeline","source":"Business Wire","summary":"GenSight Biologics Appoints Elsy Boglioli to Its Board of Directors - Business Wire","headline":"GenSight Biologics Appoints Elsy Boglioli to Its Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}